Moshe Orenstein, MD, gives a brief overview of an exciting upcoming Targeted Oncology Virtual Tumor Board series titled "Advances in Frontline Treatment for Advanced Renal Cell Carcinoma."
EP. 1: Risk Stratification of Patients with Advanced Renal Cell CarcinomaAugust 29th 2022
Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.
EP. 2: Comparing Approved First-Line IO-TKI and IO-IO Combination Treatment Regimens in Advanced Clear Cell RCCAugust 29th 2022
Dr Nizar Tannir compares data among the 4 approved first-line I/O combination therapy regimens in advanced clear cell RCC.
EP. 4: Selecting a Treatment Regimen for Favorable Risk Advanced Clear Cell RCCSeptember 7th 2022
Moshe Ornstein, MD, MA, explains the factors he considers when deciding on a combination treatment regimen for a patient with favorable-risk advanced clear cell RCC.
EP. 5: Single-Agent TKI Therapy in Favorable Risk Advanced Clear Cell RCCSeptember 12th 2022
Drs Tannir, Tykodi, and Ornstein debate whether single-agent TKI therapies still have a place in advanced clear cell RCC treatment, especially for favorable-risk patients.
EP. 6: Frontline Therapy in Advanced Clear Cell RCC: The CLEAR TrialSeptember 12th 2022
Scott Tykodi, MD, PhD, reviews data from the CLEAR trial investigating 2 IO combination therapies for advanced renal cell carcinoma treatment.
EP. 7: Rationale for Lenvatinib plus Pembrolizumab Therapy in Frontline Setting in Advanced Clear Cell RCCSeptember 20th 2022
Dr Moshe Ornstein shares his take on the survival, efficacy, and toxicity data of the CLEAR trial in advanced clear cell RCC.
EP. 9: IO-TKI Combination Therapies: Are They Synergistic or Additive?September 29th 2022
Drs Tannir and Tykodi share their differing views on the effect an IO and a TKI agent have when combined for advanced clear cell RCC treatment.
EP. 10: Managing Adverse Effects During a Lenvatinib plus Pembrolizumab Combination Therapy RegimenSeptember 29th 2022
Dr Scott Tykodi muses on how he would alter treatment for a patient with advanced clear cell RCC after side effects develop.
EP. 11: Treatment Regimens for Patients with Advanced Clear Cell RCC and Bone or Liver MetastasisOctober 6th 2022
Key opinion leaders discuss the options for patients with advanced clear cell RCC who have higher-risk metastatic disease.
EP. 12: Advanced Clear Cell RCC with Intermediate-Risk and the CHECKMATE-214 TrialOctober 6th 2022
Nizar Tannir, MD, presents the case of a 57-year-old patient with intermediate-risk advanced clear cell RCC, and Scott Tykodi, MD, PhD, presents data from the CheckMate 214 trial.
EP. 15: Tolerability of IO/TKI Combination Therapy for Advanced Clear Cell RCCOctober 17th 2022
An expert explains how he assesses a patient’s tolerability of the IO-TKI combination regimens and at what point he discontinues treatment.
EP. 17: Selecting an Appropriate Combination Therapy for Patients with Advanced Clear Cell RCCOctober 24th 2022
The panel discusses which of the four approved combination regimens in advanced clear cell RCC they would choose for higher-risk patients, and the factors that play into the decision.